GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak

If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void